Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Zirconium Cyclosilicate in Heart Failure
NCT03532009Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Jun 2018
- Primary completion
- May 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) comparing Sodium Zirconium Cyclosilicate (ZS) with Placebo (2 arms). Primary endpoint: Percentage of Patients Receiving Different Categories of RAASi Treatments at 3 months. Started Jun 2018; status: terminated.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03532009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03532009.